# US 2017/0000870 A1 · Combination therapy for immunostimulation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0000870 A1
- Document ID: US20170000870A1
- Status: Published application
- Kind: A1
- Application number: 15/206,488
- Filed: 2016-07-11
- Published: 2017-01-05
- Earliest claimed: 2004-09-02
- Assignees: CureVac AG
- Applicants: CureVac AG
- Inventors: Ingmar HOERR; Steve PASCOLO
- Web page: https://patentgrep.com/patent/US20170000870A1

## CPC

- A61K 39/0011: {Cancer antigens}
- A61K 38/1841: {Transforming growth factor [TGF]}
- A61K 38/19: Cytokines; Lymphokines; Interferons
- A61K 38/20: Interleukins [IL]
- A61K 38/21: Interferons {[IFN]}
- A61K 39/001106: {Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4}
- A61K 39/00115: {Apoptosis related proteins, e.g. survivin or livin}
- A61K 39/001153: {Wilms tumor 1 [WT1]}
- A61K 39/001156: {Tyrosinase and tyrosinase related proteinases [TRP-1 or TRP-2]}
- A61K 39/001157: {Telomerase or TERT [telomerase reverse transcriptase]}
- A61K 39/00117: {Mucins, e.g. MUC-1}
- A61K 39/001182: {Carcinoembryonic antigen [CEA]}
- A61K 39/001184: {Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE}
- A61K 39/001186: {MAGE}
- A61K 39/001188: {NY-ESO}
- A61K 39/001189: {PRAME}
- A61K 39/001191: {Melan-A/MART}
- A61K 39/001192: {Glycoprotein 100 [Gp100]}
- A61K 39/001194: {Prostate specific antigen [PSA]}
- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/04: Antibacterial agents
- A61P 31/12: Antivirals
- A61P 33/02: Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P 35/00: Antineoplastic agents
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61K 2039/53: {DNA (RNA) vaccination}
- A61K 2039/54: {characterised by the route of administration}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- A61K 2039/55522: {Cytokines; Lymphokines; Interferons}
- A61K 2039/55561: {CpG containing adjuvants; Oligonucleotide containing adjuvants}
- A61K 2039/572: {cytotoxic response}
- A61K 2039/6031: {Proteins}
- A61K 2039/70: {Multivalent vaccine}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a method for immunostimulation in a mammal which comprises a. administration of at least one mRNA containing a region which codes for at least one antigen of a pathogen or at least one tumour antigen, and b. administration of at least one cytokine, at least one cytokine mRNA, at least one CpG DNA or at least one adjuvant RNA. The invention likewise relates to a product and a kit comprising the mRNA and cytokine or cytokine mRNA or CpG DNA or adjuvant RNA of the invention.

## Claims

### Claim 1

A method of stimulating an antitumor immune response in a subject comprising administering an effective amount of a cell-free composition comprising mRNA encoding an Survivin antigen to a subject in need thereof, thereby stimulating a T-cell mediated cytotoxic anticancer immune response in the subject.

### Claim 2 (depends on 1)

The method of claim 1, wherein the subject has a cancer.

### Claim 3 (depends on 2)

The method of claim 2, wherein the cancer is a lung cancer.

### Claim 4 (depends on 1)

The method of claim 1, wherein the composition comprises mRNA encoding at least 2, 3, 4 or 5 different tumor antigens.

### Claim 5 (depends on 1)

The method of claim 1, wherein the method further comprises administering at least 2, 3, 4 or 5 different cell-free compositions comprising mRNA encoding different tumor antigens to the subject.

### Claim 6 (depends on 1)

The method of claim 1, wherein the mRNA is complexed with as least one cationic or polyocationic agent.

### Claim 7 (depends on 6)

The method of claim 6, wherein the cationic or polyocationic agent is chosen from the group consisting of protamine, poly-L-lysine, poly-L-arginine and histones.

### Claim 8 (depends on 7)

The method of claim 7, wherein the mRNA is complexed with protamine.

### Claim 9 (depends on 1)

The method of claim 1, further comprising administering one or more adjuvant(s) to the subject.

### Claim 10 (depends on 9)

The method of claim 9, wherein the adjuvant is chosen from the group consisting of lipopolysaccharide, TNF-α, CD40 ligand, GP96, oligonucleotides with a CpG motif, aluminum hydroxide, Freund's adjuvant, a lipopeptide and a cytokine.

### Claim 11 (depends on 10)

The method of claim 10, wherein the cytokine is GM-CSF.

### Claim 12 (depends on 1)

The method of claim 1, wherein the mRNA encoding the antigen has a different nucleic acid sequence compared with the wild-type mRNA encoding the antigen.

### Claim 13 (depends on 1)

The method of claim 1, wherein the mRNA comprises a 5′ cap structure, at least one IRES and/or a poly(A+) tail of at least 25 nucleotides.

### Claim 14 (depends on 13)

The method of claim 13, wherein the mRNA comprises a 5′ cap structure and a poly(A+) tail of at least 25 nucleotides.

### Claim 15 (depends on 1)

The method of claim 1, wherein the mRNA comprises at least one 5′-stabilizing sequence and/or at least one 3′-stabilizing sequence.

### Claim 16 (depends on 15)

The method of claim 15, wherein the 5′-and/or the 3′-stabilizing sequence(s) is/are chosen from the group consisting of untranslated sequences (UTR) of the β-globin gene and a stabilizing sequence of the general formula (C/U)CCANxCCC(U/A)PyxUC(C/U)CC.

### Claim 17 (depends on 1)

The method of claim 1, wherein the mRNA comprises at least one analog of naturally occurring nucleotide selected from the group consisting of phoshorothioates, phosphoroamidates, peptide nucleotides, methylphosphates, 7-deazaguanosine, 5-methylcytosine and inosine.

### Claim 18 (depends on 1)

The method of claim 1, wherein the cell-free composition comprising mRNA is administered by injection of an aqueous solution comprising the mRNA.

### Claim 19 (depends on 1)

The method of claim 1, wherein the cell-free composition comprising mRNA is administered intradermally.

### Claim 20 (depends on 1)

The method of claim 1, wherein the cell-free composition comprising mRNA is administered two or more times.
